Collaboration Aims to Expand Globally Connected Scientific Dialogue and Accelerate Innovation in Human Health and Sustainability

Flagship Pioneering, the bioplatform innovation company, the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), National University Hospital (NUH) and the National University Health System (NUHS) today announced a research and development collaboration to advance outcomes in human health and sustainability. Flagship, NUS Medicine, NUH and NUHS outlined the goals of their collaboration via a Memorandum of Understanding (MOU) signed this week.

Flagship, NUS Medicine, NUH and NUHS expect to create, co-develop and co-resource a series of research projects over an initial five-year horizon, tapping into opportunities across Flagship's existing ecosystem of over 40 companies, and future companies founded by Flagship. Through potential secondments, internships and participation in the Flagship Fellowship program, the collaboration will also create career development and mentorship opportunities for scientists and students of NUS Medicine with Flagship.

In addition, Flagship will tap into the ecosystem of NUH and NUHS to leverage clinical data for new biological insights, test clinical hypotheses for novel impact and improved patient outcomes.  

"Our collaboration with NUS Medicine, NUH and NUHS will help us realize our goal to expand the global reach and impact of Flagship and its companies and serve as an anchor in Singapore and throughout Asia Pacific for globally connected life science innovation," said André Andonian, Chair of Asia Pacific and Strategic Advisor, Flagship Pioneering. "We are pleased to combine Flagship's signature approach to company creation and development with the scientific expertise, data reach and translational potential of NUS Medicine, NUH and NUHS. Along with our previously announced collaboration with the Agency for Science, Technology and Research (A*STAR), our work with NUS Medicine, NUH and NUHS has the potential to bring together key players across Singapore's biotech ecosystem to advance breakthroughs that impact patients and the planet."

"As integral parts of the NUHS academic health system, NUS Medicine and NUH are uniquely positioned to translate groundbreaking biomedical research seamlessly into real-world clinical solutions," said Professor Chong Yap Seng, Dean, NUS Medicine, and Deputy Chief Executive (Education & Research), NUHS. "Through this partnership with Flagship, we aim to drive greater innovation and bridge the gap between discovery and patient care. Together, we can shape a future where practice-changing innovations and transformative health solutions can benefit patients, communities and the world."